drugset / Trial / NCT07340424

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

NCT07340424 ↗

Phase 0 Recruiting 15 enrolled Xiaorong Sun
NaSingle-groupOpen-labelTreatment

Summary

This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.

Timeline

Start
2025-05-22
Primary completion
2027-04
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 225Ac-TR2205 Unknown — —